Company Performance: CEL-SCI Corporation's clinical trial results, especially for Multikine in head and neck cancer, significantly impact the stock price. Positive data boosts investor confidence, while setbacks lead to declines.

Market Sentiment: Overall market conditions and investor risk appetite affect CELJF.US. Bull markets often lift speculative stocks, while bear markets can pressure them downwards. The biotechnology sector's performance also plays a role.

Regulatory Approvals: FDA decisions regarding Multikine's approval are critical. Approval leads to commercialization and revenue, driving the stock up. Rejection or delays cause significant price drops.

Financial Status: CEL-SCI's cash position and ability to fund ongoing research and development affect investor confidence. Concerns about dilution (issuing more shares) to raise capital can depress the stock.

Competition: Progress and announcements from competitors in the head and neck cancer treatment space can affect CEL-SCI's perceived market opportunity and thus its stock price.

News and Media: Media coverage and analyst ratings influence investor perception. Positive reports can attract buyers, while negative ones can trigger selling.

Partnerships: Establishing partnerships with larger pharmaceutical companies can boost credibility and provide funding, positively impacting the stock price.

Intellectual Property: The strength and protection of CEL-SCI's patents are important. Strong IP protection gives them a competitive advantage and affects the stock's valuation.